ArticleOncology letters2018
Correlation of xeroderma pigmentosum complementation group F expression with gastric cancer and prognosis.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Article
- Construction of Molecular Subtype and Prognosis Prediction Model of Osteosarcoma Based on Aging-Related Genes.Journal of oncology · 2022Article
- XPF expression and its relationship with the risk and prognosis of colorectal cancer.Cancer cell international · 2021Article
- Article
- Expression and Clinical Significance of ERCC1 and XPF in Human Hepatocellular Carcinoma.OncoTargets and therapy · 2020Article
- Increased expression of miR-601 is associated with poor prognosis and tumor progression of gastric cancer.Diagnostic pathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Correlation of xeroderma pigmentosum complementation group F (XPF) expression with gastric cancer and prognosis was investigated. We randomly selected 76 gastric cancer patients who were admitted to the Second People's Hospital of Dezhou City and received treatment, and detected XPF expression in gastric cancer tissues (observation group) and normal gastric mucosa adjacent to tumor (control group) via immunohistochemistry. Correlation between XPF expression and clinicopathological indicators of gastric cancer was verified via single-factor Chi-square test. Cox's proportional hazard regression model was used in the analysis of influencing factors of patient's prognosis, and Kaplan-Meier was used to analyze the survival rates of XPF-positive and -negative patients. In the observation group, the XPF-positive rate was significantly higher than that in the control group with a statistically significant difference (P<0.05). Single-factor analysis showed that XPF expression was correlated with the family history and Laurén classification (P<0.05). Kaplan-Meier survival analysis revealed that the survival time of XPF-positive patients was shorter than that of XPF-negative patients (P<0.05). Multifactorial analysis using Cox's hazards model suggested that XPF was an independent factor affecting the prognosis of gastric cancer (P<0.05). In conclusion, XPF expression plays an important role in the occurrence and development of gastric cancer, and a high expression of XPF suggests a poor prognosis of gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.